News

News 2017-11-19T23:06:00+00:00

Arix Bioscience leads $30 million financing for Atox Bio

Funding to advance Reltecimod into a Phase 2 clinical study for acute kidney injury, building upon Atox Bio’s on-going Phase 3 clinical development in necrotising soft tissue infections  Arix achieves target of 12 Group Businesses by the end of 2017, successfully building a balanced group with multiple, potentially significant milestones over the next 12 months  LONDON, 4 December 2017: Arix Bioscience plc (LSE: ARIX) (“Arix [...]

December 4th, 2017|

Autolus announces publication in Nature

London, 14 November 2017 – Autolus Limited, a clinical-stage biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies, today announced the publication of an article in Nature Medicine describing a unique targeting strategy for the treatment of patients with T-cell lymphomas.

November 14th, 2017|

Sir John Banham retires from Board of Directors of Arix Bioscience plc

LONDON, 10 November 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces that Sir John Banham is retiring from his position as a Non-Executive Director of Arix Bioscience. Sir John, who is 76, has been Chairman of the Audit and Risk Committee, and has helped to oversee the Company’s growth both [...]

November 10th, 2017|

Arix Bioscience to present at two investor conferences in November

LONDON, 1 November 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience") a global healthcare and life science company supporting medical innovation, will present at two investor conferences in November: Stifel 2017 Healthcare Conference on November 15, 2017 at 11:40 a.m. ET at the Lotte New York Palace Hotel. Jonathan Peacock, Chairman, will make the presentation, and will participate in one-on-one investor meetings at the conference on [...]

November 1st, 2017|

Arix Bioscience appoints Giles Kerr to Board of Directors

LONDON, 17 October 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces the appointment of Giles Kerr as a Non-Executive Director of the Company and chairman of the Board’s Audit Committee. The appointment is with immediate effect. Giles Kerr has 36 years’ experience in finance across a broad range of industrial [...]

October 17th, 2017|

Arix Bioscience notes positive Phase I clinical and non-clinical data from Amplyx for the treatment of life-threatening fungal infections

LONDON, 10 October 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience"), a global healthcare and life science company supporting medical innovation, is pleased to note the release of positive clinical and non-clinical data by Amplyx Pharmaceuticals (“Amplyx”), an Arix Bioscience Group Business, at IDWeek 2017, held in San Diego, CA. The data showed that Amplyx’s lead candidate APX001, a novel, broad-spectrum drug in development for [...]

October 10th, 2017|

Arix Bioscience participates in $80 million Series C financing for Autolus

LONDON, 26 September 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “Arix”), a global healthcare and life science company supporting medical innovation, today announces that it has participated in an $80 million Series C financing round for Autolus Limited (“Autolus”), an Arix Bioscience Group Business. Autolus is a clinical-stage biopharmaceutical company focused on the development and commercialization of next-generation engineered T-cell therapies. Arix Bioscience [...]

September 26th, 2017|

Arix Bioscience plc notes positive clinical study announcements from Autolus Limited

LONDON, 18 September 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience"), a global healthcare and life science company supporting medical innovation, is pleased to note two positive press releases today by Autolus Limited (“Autolus”), an Arix Bioscience Group Business, announcing clinical progress across its portfolio. The first release today from Autolus announced the completion of the first-dose cohort of its Phase I/II study of AUTO2, [...]

September 18th, 2017|

Arix Bioscience hosts Capital Markets Meeting today

LONDON, 18 September, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “Arix”), a global healthcare and life science company supporting medical innovation, is today hosting its inaugural Capital Markets Meeting for investors and analysts in London. Joe Anderson, Chief Executive Officer, and Jonathan Peacock, Chairman, will provide an update on Arix Bioscience’s strategy and progress to date. The event will also include presentations from [...]

September 18th, 2017|

Arix Bioscience to Host Capital Markets Meeting in London, 18 September 2017

LONDON, 14 September, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, will host its inaugural Capital Markets Meeting for investors and analysts in London on 18 September 2017. Dr Joe Anderson, Chief Executive Officer of Arix Bioscience, and Jonathan Peacock, Chairman of Arix Bioscience, will provide an update on the Company’s strategy [...]

September 14th, 2017|